|
1
|
Pelosi G, Sonzogni A, De Pas T, Galetta D,
Veronesi G, Spaggiari L, Manzotti M, Fumagalli C, Bresaola E, Nappi
O, et al: Review article: Pulmonary sarcomatoid carcinomas: A
practical overview. Int J Surg Pathol. 18:103–120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schrock AB, Li SD, Frampton GM, Suh J,
Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, et al:
Pulmonary sarcomatoid carcinomas commonly harbor either potentially
targetable genomic alterations or high tumor mutational burden as
observed by comprehensive genomic profiling. J Thorac Oncol.
12:932–942. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yendamuri S, Caty L, Pine M, Adem S,
Bogner P, Miller A, Demmy TL, Groman A and Reid M: Outcomes of
sarcomatoid carcinoma of the lung: A surveillance, epidemiology,
and end results database analysis. Surgery. 152:397–402. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis WD; World Health Organization, :
International Agency for Research on Cancer, International
Association for the Study of Lung Cancer. And International Academy
of Pathology: Pathology and genetics of tumours of the lung,
pleura, thymus and heart. IARC Press, Oxford University Press
(distributor); Lyon, Oxford: 2004
|
|
5
|
Terra SB, Jang JS, Bi L, Kipp BR, Jen J,
Yi ES and Boland JM: Molecular characterization of pulmonary
sarcomatoid carcinoma: Analysis of 33 cases. Mod Pathol.
29:824–831. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weissferdt A: Pulmonary sarcomatoid
carcinomas: A review. Adv Anat Pathol. 25:304–313. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lucas DR, Pass HI, Madan SK, Adsay NV,
Wali A, Tabaczka P and Lonardo F: Sarcomatoid mesothelioma and its
histological mimics: A comparative immunohistochemical study.
Histopathology. 42:270–279. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Toki MI, Merritt CR, Wong PF, Smithy JW,
Kluger HM, Syrigos KN, Ong GT, Warren SE, Beechem JM and Rimm DL:
High-plex predictive marker discovery for melanoma
immunotherapy-treated patients using digital spatial profiling.
Clin Cancer Res. 25:5503–5512. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vieira T, Antoine M, Ruppert AM, Fallet V,
Duruisseaux M, Giroux Leprieur E, Poulot V, Rabbe N, Sclick L,
Beau-Faller M, et al: Blood vessel invasion is a major feature and
a factor of poor prognosis in sarcomatoid carcinoma of the lung.
Lung Cancer. 85:276–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Decalf J, Albert ML and Ziai J: New tools
for pathology: A user's review of a highly multiplexed method for
in situ analysis of protein and RNA expression in tissue. J Pathol.
247:650–661. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alborelli I, Leonards K, Rothschild SI,
Leuenberger LP, Savic Prince S, Mertz KD, Poechtrager S, Buess M,
Zippelius A, Läubli H, et al: Tumor mutational burden assessed by
targeted NGS predicts clinical benefit from immune checkpoint
inhibitors in non-small cell lung cancer. J Pathol. 250:19–29.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cao D, Xu H, Xu X, Guo T and Ge W: High
tumor mutation burden predicts better efficacy of immunotherapy: A
pooled analysis of 103078 cancer patients. Oncoimmunology.
8:e16292582019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heeke S, Benzaquen J, Long-Mira E, Audelan
B, Lespinet V, Bordone O, Lalvée S, Zahaf K, Poudenx M, Humbert O,
et al: In-house implementation of tumor mutational burden testing
to predict durable clinical benefit in non-small cell lung cancer
and melanoma patients. Cancers (Basel). 11:12712019. View Article : Google Scholar
|
|
14
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hannigan G, Troussard AA and Dedhar S:
Integrin-linked kinase: A cancer therapeutic target unique among
its ILK. Nat Rev Cancer. 5:51–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fenouille N, Tichet M, Dufies M, Pottier
A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari
A, et al: The epithelial-mesenchymal transition (EMT) regulatory
factor SLUG (SNAI2) is a downstream target of SPARC and AKT in
promoting melanoma cell invasion. PLoS One. 7:e403782012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liang X, Li Q, Xu B, Hu S, Wang Q, Li Y,
Zong Y, Zhang S and Li C: Mutation landscape and tumor mutation
burden analysis of Chinese patients with pulmonary sarcomatoid
carcinomas. Int J Clin Oncol. 24:1061–1068. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Velcheti V, Rimm DL and Schalper KA:
Sarcomatoid lung carcinomas show high levels of programmed death
ligand-1 (PD-L1). J Thorac Oncol. 8:803–805. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gopal S, Veracini L, Grall D, Butori C,
Schaub S, Audebert S, Camoin L, Baudelet E, Radwanska A,
Beghelli-de la Forest Divonne S, et al: Fibronectin-guided
migration of carcinoma collectives. Nat Commun. 8:141052017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang WY, Twu CW, Liu YC, Lin HH, Chen CJ
and Lin JC: Fibronectin promotes nasopharyngeal cancer cell
motility and proliferation. Biomed Pharmacother. 109:1772–1784.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rick JW, Chandra A, Dalle Ore C, Nguyen
AT, Yagnik G and Aghi MK: Fibronectin in malignancy:
Cancer-specific alterations, protumoral effects, and therapeutic
implications. Semin Oncol. 46:284–290. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park SY, Kim MJ, Park SA, Kim JS, Min KN,
Kim DK, Lim W, Nam JS and Sheen YY: Combinatorial TGF-β attenuation
with paclitaxel inhibits the epithelial-to-mesenchymal transition
and breast cancer stem-like cells. Oncotarget. 6:37526–37543. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sarkar FH, Li Y, Wang Z and Kong D:
Pancreatic cancer stem cells and EMT in drug resistance and
metastasis. Minerva Chir. 64:489–500. 2009.PubMed/NCBI
|
|
24
|
Terashima M, Sakai K, Togashi Y, Hayashi
H, De Velasco MA, Tsurutani J and Nishio K: Synergistic antitumor
effects of S-1 with eribulin in vitro and in vivo for
triple-negative breast cancer cell lines. Springerplus. 3:4172014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Manzotti G, Torricelli F, Benedetta D,
Lococo F, Sancisi V, Rossi G, Piana S and Ciarrocchi A: An
Epithelial-to-mesenchymal transcriptional switch triggers evolution
of pulmonary sarcomatoid carcinoma (PSC) and identifies dasatinib
as new therapeutic option. Clin Cancer Res. 25:2348–2360. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Singh M, Yelle N, Venugopal C and Singh
SK: EMT: Mechanisms and therapeutic implications. Pharmacol Ther.
182:80–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kordes S, Pollak MN, Zwinderman AH, Mathôt
RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ and Wilmink JW:
Metformin in patients with advanced pancreatic cancer: A
double-blind, randomised, placebo-controlled phase 2 trial. Lancet
Oncol. 16:839–847. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Andersson Y, Inderberg EM, Kvalheim G,
Herud TM, Engebraaten O, Flatmark K, Dueland S and Fodstad Ø:
Immune stimulatory effect of anti-EpCAM immunotoxin-improved
overall survival of metastatic colorectal cancer patients. Acta
Oncol. 59:404–409. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mau-Sørensen M, Dittrich C, Dienstmann R,
Lassen U, Büchler W, Martinius H and Tabernero J: A phase I trial
of intravenous catumaxomab: A bispecific monoclonal antibody
targeting EpCAM and the T cell coreceptor CD3. Cancer Chemother
Pharmacol. 75:1065–1073. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Carnemolla B, Neri D, Castellani P,
Leprini A, Neri G, Pini A, Winter G and Zardi L: Phage antibodies
with pan-species recognition of the oncofoetal angiogenesis marker
fibronectin ED-B domain. Int J Cancer. 68:397–405. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Halin C, Rondini S, Nilsson F, Berndt A,
Kosmehl H, Zardi L and Neri D: Enhancement of the antitumor
activity of interleukin-12 by targeted delivery to neovasculature.
Nat Biotechnol. 20:264–269. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tsung K, Meko JB, Peplinski GR, Tsung YL
and Norton JA: IL-12 induces T helper 1-directed antitumor
response. J Immunol. 158:3359–3365. 1997.PubMed/NCBI
|
|
33
|
Brunda MJ, Luistro L, Warrier RR, Wright
RB, Hubbard BR, Murphy M, Wolf SF and Gately MK: Antitumor and
antimetastatic activity of interleukin 12 against murine tumors. J
Exp Med. 178:1223–1230. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fabbrini M, Trachsel E, Soldani P, Bindi
S, Alessi P, Bracci L, Kosmehl H, Zardi L, Neri D and Neri P:
Selective occlusion of tumor blood vessels by targeted delivery of
an antibody-photosensitizer conjugate. Int J Cancer. 118:1805–1813.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xing Y, Qi J, Deng S, Wang C, Zhang L and
Chen J: Small interfering RNA targeting ILK inhibits metastasis in
human tongue cancer cells through repression of
epithelial-to-mesenchymal transition. Exp Cell Res. 319:2058–2072.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yuan Y, Xiao Y, Li Q, Liu Z, Zhang X, Qin
C, Xie J, Wang X and Xu T: In vitro and in vivo
effects of short hairpin RNA targeting integrin-linked kinase in
prostate cancer cells. Mol Med Rep. 8:419–424. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee SL, Hsu EC, Chou CC, Chuang HC, Bai
LY, Kulp SK and Chen CS: Identification and characterization of a
novel integrin-linked kinase inhibitor. J Med Chem. 54:6364–6374.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Edwards LA, Woo J, Huxham LA, Verreault M,
Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, et al:
Suppression of VEGF secretion and changes in glioblastoma
multiforme microenvironment by inhibition of integrin-linked kinase
(ILK). Mol Cancer Ther. 7:59–70. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Younes MN, Kim S, Yigitbasi OG, Mandal M,
Jasser SA, Dakak Yazici Y, Schiff BA, El-Naggar A, Bekele BN, Mills
GB and Myers JN: Integrin-linked kinase is a potential therapeutic
target for anaplastic thyroid cancer. Mol Cancer Ther. 4:1146–1156.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tsoumas D, Nikou S, Giannopoulou E,
Champeris Tsaniras S, Sirinian C, Maroulis I, Taraviras S, Zolota
V, Kalofonos HP and Bravou V: ILK expression in colorectal cancer
is associated with EMT, cancer stem cell markers and
chemoresistance. Cancer Genomics Proteomics. 15:127–141.
2018.PubMed/NCBI
|
|
41
|
Iwasa T, Tsurutani J, Watanabe S, Kato R,
Mizuno Y, Kojima Y, Takashima T, Matsunami N, Morimoto T, Yamamura
J, et al: Multicentre, phase II study of eribulin in combination
with S-1 in patients with advanced breast cancer. BMC Cancer.
19:9622019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sakiyama T, Tsurutani J, Iwasa T, Kawakami
H, Nonagase Y, Yoshida T, Tanaka K, Fujisaka Y, Kurata T, Komoike
Y, et al: A phase I dose-escalation study of eribulin and S-1 for
metastatic breast cancer. Br J Cancer. 112:819–824. 2015.
View Article : Google Scholar : PubMed/NCBI
|
